Ortoma launches OTS 5 according to plan

STOCKHOLM, Dec. 14, 2020

OTS 5 is the result of development of, primarily, software and hardware during the greater part of this year. Market needs have continuously been integrated into the development process. Development of accessories to OTS was initiated last year and includes advanced product requirements and extensive regulatory requirements.

Updated OTS 5 includes a large number of improvements to previous existing functionality and a number of new functionalities. The new version provides improved usability both before and during surgery. OTS 5 includes both an Ortoma Plan and an Ortoma Guide.

"OTS makes it possible for the surgeon to plan in 3D with high accuracy prior to surgery, and during surgery get assistance with correct placement of the implant in the patient. The system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries - and thus better long-term survival rates for the implant. The system can easily be integrated into the processes and routines that are currently used in surgeries," says Gunnar Németh, Chairman of the Board of Ortoma and Professor emeritus and former Head of Orthopedic Surgery at Karolinska University Hospital and Karolinska Institute. 

In the software Ortoma Plan, which is used before surgery, workflows have been improved and functionality added. The system now includes, for example, an optimized algorithm based on artificial intelligence to assist the surgeon to select implant and optimize its position in a shorter time.

In Ortoma Guide, which is used during surgery, both software and the new accessories to OTS, which are used with the surgical instruments, have been improved. The workflow in the software has been optimized to be more intuitive. The new accessories to OTS reduce the time for preparing for surgery significantly. Furthermore, the accessories can be produced in large volumes at low cost, which substantially increases the competitiveness of the system.

"OTS 5 is the result of feedback from clinical partners and market research identifying the needs of potential commercialization partners. We are convinced that the updated platform will have a big impact on both patients and care providers globally. In addition, all parts of the system can now be sold at very competitive prices. I am proud that we have completed this launch during the ongoing pandemic, with increased scope and within the original planned timeline. Our staff has done a great job" says Linus Byström, CEO of Ortoma.